Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenalidomide and Azacitidine in Older AML
NCT01358734Phase 2Completed
- Sponsor
- Celgene Corporation
- Start
- Apr 2012
- Primary completion
- May 2015
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of lenalidomide in acute myeloid leukemia (AML), sponsored by Celgene Corporation. Started Apr 2012; status: completed.
02
Drugs
lenalidomide
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT01358734.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01358734.